Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | MMP3 | P08254 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP7 | P09237 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31693351 | 1.00 | POLB (0.45) | POLBSMN1; SMN2LMNAGAAKMT2A | |
| SCHEMBL31131213 | 0.92 | SMN1; SMN2 (0.47) | POLBSMN1; SMN2LMNAGAAKMT2A | |
| SCHEMBL2360585 | 0.92 | SMN1; SMN2 (0.47) | POLBSMN1; SMN2LMNAGAAKMT2A | |
| SCHEMBL9051469 | 0.88 | SMN1; SMN2 (0.43) | POLBSMN1; SMN2LMNAGAAKMT2A | |
| SCHEMBL10372097 | 0.88 | GAA (0.50) | POLBSMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL4768470 | 0.86 | SMN1; SMN2 (0.48) | POLBSMN1; SMN2LMNAGAAKMT2A | |
| SCHEMBL3313643 | 0.84 | SMN1; SMN2 (0.52) | POLBSMN1; SMN2LMNAGAAKMT2A | |
| SCHEMBL3656085 | 0.82 | POLB (0.43) | POLBSMN1; SMN2LMNAGAAKMT2A | |
| SCHEMBL18173570 | 0.81 | CYP2D6 (0.46) | POLBGAAKMT2AMAPTCYP1A2 | |
| SCHEMBL30497646 | 0.81 | POLB (0.51) | POLBSMN1; SMN2LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544382-B2 | 2, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitor | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2026-02-10 | — | — | US | disclosed |
| US-20220378799-A1 | 2, 4, 6-TRI-SUBSTITUTED PYRIMIDINE COMPOUND AS ATR KINASE INHIBITOR | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2022-12-01 | — | — | US | disclosed |
| US-10280174-B2 | Salt of fused pyrimidine compound and crystal thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-05-07 | — | — | US | disclosed |
| US-20180127428-A1 | NOVEL SALT OF FUSED PYRIMIDINE COMPOUND AND CRYSTAL THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-10 | — | — | US | disclosed |
| US-9908889-B2 | Salt of fused pyrimidine compound and crystal thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-03-06 | — | — | US | disclosed |
| US-20170044166-A1 | NOVEL SALT OF FUSED PYRIMIDINE COMPOUND AND CRYSTAL THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-02-16 | — | — | US | disclosed |
| WO-2016170545-A1 | PROCESS FOR THE PREPARATION OF 1-[(3R)-3-[4-AMINO-3-(4-PHENOXYPHENVL)-1H- PVRAZOLO[3,4-D]PYRINIIDIN-1-Y1]-1-PIPERIDINVL]-2-PROPEN-1-ONE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-10-27 | — | — | WO | disclosed |
| EP-2539346-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| WO-2011104337-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044166-A1 | NOVEL SALT OF FUSED PYRIMIDINE COMPOUND AND CRYSTAL THEREOF | BTK, LCK, SYK | POLB 3246/4885SMN1; SMN2 4748/4885LMNA 4807/4885 |
| US-20180127428-A1 | NOVEL SALT OF FUSED PYRIMIDINE COMPOUND AND CRYSTAL THEREOF | BTK, LCK, SYK | POLB 3246/4885SMN1; SMN2 4748/4885LMNA 4807/4885 |
| US-12544382-B2 | 2, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitor | ATR, CHEK1, CHEK2 | POLB 107/4885SMN1; SMN2 1690/4885LMNA 1235/4885 |
| US-20220378799-A1 | 2, 4, 6-TRI-SUBSTITUTED PYRIMIDINE COMPOUND AS ATR KINASE INHIBITOR | ATR, CHEK2, CHEK1 | POLB 122/4885SMN1; SMN2 1914/4885LMNA 1773/4885 |
| US-10280174-B2 | Salt of fused pyrimidine compound and crystal thereof | BTK, LCK, SYK | POLB 2851/4885SMN1; SMN2 4669/4885LMNA 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.